Comparative real-world outcomes of durvalumab plus gemcitabine/cisplatin versus pembrolizumab plus gemcitabine/cisplatin as first-line therapy for advanced biliary tract cancer.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 133 - 199 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |